| Human immunodeficiency virus I infection
Genvoya vs Tivicay
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Genvoya vs Tivicay with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTivicay has a higher rate of injection site reactions vs Genvoya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tivicay but not Genvoya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Genvoya
Tivicay
At A Glance
Oral
Once daily
Fixed-dose combination: INSTI + CYP3A inhibitor + NRTIs
Oral
Once daily (or twice daily with certain inducers)
Integrase strand transfer inhibitor (INSTI)
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (150 mg EVG, 150 mg COBI, 200 mg FTC, 10 mg TAF) orally once daily with food in patients weighing at least 25 kg with creatinine clearance >=30 mL/min, or adults with creatinine clearance <15 mL/min receiving chronic hemodialysis (administer after hemodialysis on dialysis days).
Human immunodeficiency virus I infection (treatment-naive or INSTI-naive adults) 50 mg orally once daily, with or without food. Adjust to 50 mg twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (INSTI-experienced adults with resistance) 50 mg orally twice daily, with or without food, combined with optimized background therapy.
Human immunodeficiency virus I infection (pediatric patients 3 kg to <6 kg) TIVICAY PD 5 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 6 kg to <10 kg) TIVICAY PD 15 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 10 kg to <14 kg) TIVICAY PD 20 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 14 kg to <20 kg) TIVICAY PD 25 mg orally once daily or TIVICAY tablets 40 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients >=20 kg) TIVICAY PD 30 mg orally once daily or TIVICAY tablets 50 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (virologically suppressed adults switching to dual therapy) 50 mg orally once daily in combination with rilpivirine 25 mg once daily, with or without food.
Contraindications
- Alfuzosin
- Carbamazepine
- Phenobarbital
- Phenytoin
- Rifampin
- Lurasidone
- Pimozide
- Dihydroergotamine
- Ergotamine
- Methylergonovine
- St. John's wort
- Lomitapide
- Lovastatin
- Simvastatin
- Sildenafil for pulmonary arterial hypertension
- Triazolam
- Orally administered midazolam
- Hypersensitivity to dolutegravir
- Coadministration with dofetilide
Adverse Reactions
Most common (>=5%) Nausea, diarrhea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=2%, treatment-naive) Insomnia, headache, diarrhea, nausea, fatigue, rash
Serious Hypersensitivity reactions, hepatotoxicity, immune reconstitution syndrome
Postmarketing Sideroblastic anemia, acute liver failure, weight increased, arthralgia, myalgia, anxiety
Pharmacology
GENVOYA is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor that prevents HIV-1 DNA integration into host genomic DNA), cobicistat (a CYP3A inhibitor that enhances elvitegravir exposure), emtricitabine (a nucleoside reverse transcriptase inhibitor that causes viral DNA chain termination), and tenofovir alafenamide (a prodrug converted to tenofovir diphosphate, which inhibits reverse transcriptase through DNA chain termination).
Dolutegravir is an HIV-1 integrase strand transfer inhibitor that blocks the strand transfer step of retroviral DNA integration essential for HIV replication by binding to the integrase active site.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Genvoya
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Tivicay
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Genvoya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Tivicay
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Genvoya
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Tivicay
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GenvoyaView full Genvoya profile
TivicayView full Tivicay profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.